Neogap's patented method opens for new individualized treatment of MS
A recent study shows that a part of Neogap Therapeutics' patented method for developing individualized immunotherapy for cancer treatment can also be used to identify which immune cells are involved in autoimmune diseases. In the study, four new target molecules for MS have been discovered.Multiple sclerosis, MS, is a chronic inflammatory disease of the central nervous system. The condition is driven by immune cells mistakenly attacking the tissue surrounding nerve cells in the brain and spinal cord, leading to severe neurological symptoms. Today, there is no cure for MS. The aim of the